logo
Science Portal
Copyright © Médecins Sans Frontières
v2.1.5209.produseast1
About MSF Science Portal
About
Contact Us
Frequently Asked Questions (FAQs)
Privacy Policy
Terms of Use
Copyright © Médecins Sans Frontières
v2.1.5209.produseast1
Showing 1 - 4 of 4 Items
Showing 1 - 4 of 4 Items
Sort By: Relevance
  • Newest to oldest
  • Oldest to newest
  • Relevance
Journal Article
|
Letter

Revised definitions of multidrug-resistant tuberculosis treatment outcomes: closer to the reality?

Bastard M, Bonnet MMB, du Cros PAK, Khamraev AK, Hayrapetyan A,  et al.
2015-02-01 • American Journal of Respiratory and Critical Care Medicine
2015-02-01 • American Journal of Respiratory and Critical Care Medicine
Journal Article
|
Research

Outcomes of HIV-infected versus HIV-non-infected patients treated for drug-resistance tuberculosis: Multicenter cohort study

Bastard M, Sanchez-Padilla E, du Cros PAK, Khamraev AK, Parpieva N,  et al.
2018-03-08 • PLOS One
2018-03-08 • PLOS One
The emergence of resistance to anti-tuberculosis (DR-TB) drugs and the HIV epidemic represent a serious threat for reducing the global burden of TB. Although data on HIV-negative DR-TB t...
Journal Article
|
Research

What is the best culture conversion prognostic marker for patients treated for multidrug-resistant tuberculosis?

Bastard M, Sanchez-Padilla E, Hayrapetyan A, Kimenye K, Khurkhumal S,  et al.
2019-10-01 • International Journal of Tuberculosis and Lung Disease
2019-10-01 • International Journal of Tuberculosis and Lung Disease
INTRODUCTION
Identification of good prognostic marker for tuberculosis (TB) treatment response is a necessary step on the path towards a surrogate marker to reduce TB trial duration....
Journal Article
|
Research

Identification of patients who could benefit from bedaquiline or delamanid: a multisite MDR-TB cohort study

Bonnet MMB, Bastard M, du Cros PAK, Khamraev AK, Kimenye K,  et al.
2016-02-01 • International Journal of Tuberculosis and Lung Disease
2016-02-01 • International Journal of Tuberculosis and Lung Disease
BACKGROUND
The World Health Organization recommends adding bedaquiline or delamanid to multidrug-resistant tuberculosis (MDR-TB) regimens for which four effective drugs are not avail...